Visit your local Alkaloid website

According to the unaudited standalone Income Statement, in the period January- March the sales reached the amount of MKD 2,101,073,373 - 14% up on the same period last year. Earnings before interest, taxes, depreciation and amortization (EBITDA), which amount to MKD 422,772,099 marked an increase of roughly 16%, whereas the net profit amounting to MKD 247,475,979 rose by 15%.

In the period January – March the total consolidated sales reached MKD 2,833,475,867 – an increase of 15% compared to the same period last year. Consolidated sales in the domestic market increased 2%, while the total consolidated export of the company increased by 23%. Out of the total consolidated sales, 32% were realized in the domestic market, while the foreign markets account for 68%. The breakdown by region shows that the countries of South-East Europe account for 31% of the sales, Russia and CIS – 10%, 24% of the sales were realized in the countries from Western Europe (EU and EFTA), while the other markets account for 2% of the total consolidated sales. Noticeable rise was seen in Great Britain reaching sales of MKD 81,096,751 - increased by 4.8 times, Georgia reaching sales of MKD 9,428,863 - increased by 2 times and Poland with sales of MKD 19,183,607 – increased by 72% compared to the same period last year. Growth in sales was also marked in the following export markets: Hungary - 63%, Russia – 58%, Ukraine – 57%, Bulgaria - 49%, Germany - 42%, Armenia – 36%, Slovenia – 22%, Romania – 19%, USA – 14%, etc. The significant increase in export sales in the first quarter of 2019 is partially due to the mandatory serialization of products for the EU markets which started from 09.02.2019.

The breakdown of total consolidated sales by group of products shows that the best sellers are the products from the segment Pharmaceuticals – 88%, with OTC products accounting for 20%, cardiovascular products - 17%, antibiotics - 19%, neurological products – 13% etc. The Chemistry Cosmetics Botanicals segment accounts for 12% of the total consolidated sales, or more precisely Chemistry – 2%, Cosmetics – 7% and Botanicals – 3%.

Consolidated earnings before interest, taxes, depreciation and amortization (EBITDA), which reached MKD 490,980,742 saw an increase of 19%, whereas the net consolidated profit amounting to MKD 294,542,101 went up by 19%.

The total investments in non-current assets for the period January – March 2019 amounted to MKD 193,866,065.

In the period January – March 2019 Alkaloid recruited 55 new employees in the Republic of North Macedonia.

In March 2019 the management board of Alkaloid AD Skopje reached a decision on approval and payment of holiday allowances for its employees. The amount payed was MKD 27,709 gross or MKD 24,938 net.